• 作者： 馬正平; 葉明陽; 于大雄; 姜淑媛; 王成俊; 張聖原; 韓韶華
• 作者服務機構： 國防醫學院; 三軍總醫院癌症研究室及泌尿外科
• 中文摘要： 以一人類膀胱癌細胞株（TSGH-8301）作為免疫原利用融合瘤技術獲得一屬亞型之老鼠單源抗體1G3.10.此單源抗體可與近 40%(13/34)之人類膀胱癌腫瘤組織反應，但很少與其他腫瘤組織或正常組織產生反應。由紅血球凝集反應及抗體吸附試驗，得知此抗體可專對A及AB型紅血球表面抗原產生反應。此抗體所認知之腫瘤抗原經放射免疫沈澱法(RIP)及薄層色相分析法(TLC)分析後得知為一糖蛋白(M.W. 30, 54, 108 KD)及中性糖脂(Rf. 0.67-0.83)之混合物。進一步由螢光激活細胞分類儀(FACS), 4-hr Cr釋放測定抗體媒介性細胞毒殺作用(ADCC)及補體媒介性細胞毒殺作用(CDC)等試驗後，得知此認知A型血型相關抗原之單源抗體163.10可有殺死膀胱癌細胞之能力。這些結果提示此抗體可於將來發展研究應用於人類膀胱癌病人腫瘤之診斷及治療。
• 英文摘要： A mouse monoclonal antibody. designated 1G3.10, directed against a human urinary bladder cancer cellline TSGH-8301 was generated using the conventional hybridoma technique. It was of the subclass with arestricted specificity to bladder cancer and several epithelial cancers, as detected on a panel of various cell linesand tissues by radioimmunoassay and indirect immunofluorescence methods. It also exhibited a strong bindingactivity to human group A red blood cells, as demonstrated in hemagglutination and absorption tests. Ra-dioimmunoprecipitation and thin-layer chromatography revealed that the antigens recognized by the antibodyare a mixture of glycopeptides (M.W. 30, 54, and 108 KD) and glycolipid (retardation factor 0.67-0.83). Froma fluorescence activated cell sorter (FACS) study, direct killing of tumor cells by the antibody at a concentra-tion of more than 10 ug/ml was observed. This antibody could also mediate both antibody-dependent cellularcytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in vitro when tested in a 4-hr Cr-release test. These results suggest that the monoclonal antibody 1G3.10 may provide an agent for furtherimmunodiagnosis and the treatment of human bladder cancer.
• 中文關鍵字： blood group-A related antigen; bladder carcinoma
• 英文關鍵字： --